South Africa recalls J&J's cough syrup sold in six African nations after suspected toxicity


  • World
  • Sunday, 14 Apr 2024

FILE PHOTO: The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid/File Photo

(Reuters) - South Africa's health regulator said on Saturday it is recalling batches of Johnson & Johnson's children's cough syrup after detection of high levels of diethylene glycol.

The affected batches were sold in South Africa, Eswatini, Rwanda, Kenya, Tanzania and Nigeria, the statement added.

The recall follows a report by the regulator's Nigerian counterpart on Wednesday, which first detected the toxin in a batch of Benylin Paediatric Syrup.

Kenya and Nigeria have already issued recalls for the same syrup, which is used in the treatment of hay fever and other allergic conditions affecting the upper respiratory tract.

Kenvue, which now owns the Benylin brand after a spin-off from J&J last year, did not immediately respond to a Reuters request for comment.

High levels of diethylene glycol in cough syrup has been linked to the deaths of dozens of children in Gambia, Uzbekistan and Cameroon since 2022 in one of the world's worst waves of poisoning from oral medication.

(Reporting by Utkarsh Shetti in Bengaluru; Editing by Nick Zieminski)

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In World

Thai PM says he will speak to Trump late Friday on Cambodia clashes
Thai PM sets course for early election amid border and parliamentary unrest
Obamacare health subsidy to end as US Senate rejects dueling remedies
Torrential rains unleash widespread flooding, evacuations in Pacific Northwest
Thai PM moves to dissolve parliament, setting stage for elections
US Senate advances dozens more Trump nominees, including South Africa pick
Over 250 people quarantined in U.S. South Carolina measles outbreak
Hisense Europe sees 2025 sales up by 6 pct
U.S. stocks close mixed
2025 marked by major progress and challenges for global health: WHO chief

Others Also Read